Baird Initiates Coverage On Cardiff Oncology with Outperform Rating, Announces Price Target of $19
Baird analyst Joel Beatty initiates coverage on Cardiff Oncology (NASDAQ:CRDF) with a Outperform rating and announces Price Target of $19.
54 Biggest Movers From Yesterday
Gainers
Longeveron Inc. (NASDAQ: LGVN) shares climbed 135.3% to close at $6.87 on Thursday. Longeveron said the FDA granted rare pediatric disease designation for the company’s Lomecel-B for the treatment of hypoplastic left heart syndrome.
44 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Longeveron Inc. (NASDAQ: LGVN) jumped 157% to $7.51. Longeveron said the FDA granted rare pediatric disease designation for the company’s Lomecel-B for the treatment of hypoplastic left heart syndrome.
35 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Gevo, Inc. (NASDAQ: GEVO) shares climbed 36.6% to $7.91. Chevron and Gevo announced intent to pursue sustainable aviation fuel investment.
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi’s Pemphigus Trial Disappointment, Humanigen’s COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 8)
